|This Slide: #88 of 100|
Slide #88. Elanco, the animal health division of Eli Lilly and Company — Lohmann Animal Health
Elanco, the animal health division of Eli Lilly and Company (NYSE:LLY)
Lohmann Animal Health
Elanco, the animal health division of Eli Lilly and Company (NYSE:LLY), today announced an agreement to acquire Lohmann SE (Lohmann Animal Health), a privately-held company headquartered in Cuxhaven, Germany. Lohmann Animal Health is a global leader in the supply of poultry vaccines and also markets a range of feed additives. The acquisition will establish Elanco as a global poultry leader, solidify Elanco's vaccine presence, broaden Elanco's product offerings and significantly augment Elanco's vaccine manufacturing capabilities.
Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s human pharmaceutical products include: diabetes and other endocrinology products, immunology products, neuroscience products, oncology products, and other products. Co.'s diabetes and other endocrinology products include: Baqsimi® and Basaglar®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta® and Emgality®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux® and Verzenio®. Co.'s other products include: Cialis®.
Eli Lilly SEC Filing Email Alerts Service
Open the LLY Page at The Online Investor »
Buy (3.40 out of 4)
(ranked higher than approx. 59% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite